Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
« First ‹ Prev … 141 142 143 144 145 146 147 148 149 … Next › Last »

Prevision Policy Clips | NEHI COVID-19 Immunization Preparedness Plan Calls For Strategy Beyond “Warp Speed”

June 8, 2020

Prevision Policy Clips | CDC Flu Vaccine Contingency Plans To Counter “Difficult Time”

June 5, 2020

Prevision Policy Clips | CDC Director Testifies on COVID Response

June 4, 2020

FDA Trial Conduct Guidance Updated to Include MyStudies App, Additional Information on Remote Endpoints Amid COVID-19

June 4, 2020

FDA “Emergency Use” Process Under Review By GAO As Part Of Broad COVID Response Agenda; Democratic Critics Hit Hydroxychloroquine, Not Remdesivir

June 3, 2020

FDA “Quality Maturity” Ratings Proposal Gains Traction During Senate Finance Hearing; COVID “Spot Shortages” Add To Long-Standing Supply Issues

June 3, 2020

CMMI Oncology Care, BPCI-Advanced Payment Models Will Be Modified Due To COVID-19; No Changes To Part D Models

June 3, 2020

FDA And Congress: Bipartisan Support Tenuous After FDA Leadership Changes, But Senate Committee Steps Carefully Around Hot Topics During Inspection Hearing

June 3, 2020

Prevision Policy Clips | Novartis MS Application Delayed By Three Months; Priority Review Voucher-Supported Supplement

June 3, 2020

Expanded Access During COVID-19: FDA Advises On Ensuring Adequate Risk-Benefit Assessment For Individual Requests

June 3, 2020

Prevision Policy Clips | FDA’s “Warp Speed” Firewall Goes Two Ways: Woodcock On One Side, Hahn And Marks On The Other

June 2, 2020

Routine Immunization Catch Up Efforts May Complicate COVID-19 Response: Big Drop-Off In Measles, Other Childhood Shots After March 13

June 2, 2020

Prevision Policy Clips | FDA Pediatric Oncology Subcommittee Will Review Four Development Plans In Virtual Format June 17-18

June 1, 2020

“Orange Book” Update: FDA Soliciting Comments On Patent Listing Rules, Broader Input On Usefulness of Therapeutic Equivalence Ratings

May 29, 2020

Prevision Policy Clips | “Orange Book” Update: FDA Soliciting Comments On Usefulness Of Therapeutic Equivalence Ratings

May 29, 2020

Prevision Policy Clips | FDA’s Foreign Inspection Program Will Be Focus Of Senate Hearing

May 28, 2020

Missed User Fee Deadlines: FDA Steps Up Contingency Planning With Q&A Guidance; NDA/BLA Applicants Will Be Notified Of Delays, Generic Applicants Will Need To Ask

May 27, 2020

Advisory Committee Tracker: Empty Calendar As FDA Delays Intercept NASH Review; “Virtual” Meetings Are Still Expected This Summer

May 27, 2020

Prevision Policy Clips | Missed User Fee Deadlines: FDA Promises To Alert Sponsors Of Delays In Application Reviews Amid COVID

May 27, 2020

House Energy & Commerce Leadership Demands Warp Speed Response From Trump On How “Operation Warp Speed” Layers Onto Existing Programs

May 26, 2020

CDER Leadership Transition: Acting Director Cavazzoni Will Run Drug Center As Woodcock Focuses On COVID-19; A Try-Out That Could Become Permanent?

May 26, 2020

Prevision Policy Clips | Part D Co-Pay Cap Diabetes Demo Likely Subject Of White House Event

May 26, 2020

CDER Leadership Shuffle: Acting Director Will Be Cavazzoni

May 22, 2020

Democratic Health Care Platform 2020: “Health Security” – Not Medicare For All – Likely Focus

May 22, 2020

Prevision Policy Clips | PDUFA VII Kick-Off Meeting Set For July 23; “Virtual Meeting”

May 22, 2020
« First ‹ Prev … 141 142 143 144 145 146 147 148 149 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2026 Prevision Policy. All Rights Reserved. Privacy Policy